High Dose Therapy for Influenza Drug

Explore the groundbreaking findings on high-dose oseltamivir therapy for pandemic H1N1 influenza in critically ill patients presented at ICAAC 2013. Learn about the significantly increased viral clearance rates and the potential healthcare implications of this treatment approach. Delve into the rationale behind high-dose therapy for sensitive influenza strains, understand the patient cohort studied, and examine the biological basis for this intervention. Gain insights into the emergence of COVID-19, its impact on treatment strategies, and the importance of rapid response in viral outbreaks. Discover when to administer high-dose therapy and evaluate its cost-effectiveness. Engage with questions addressing the significance of planning in pandemic preparedness and the swift spread of viral infections.

Introduction
The Bottom Line
Why is this important
What we found
When to give it
Is it worth it
Biological rationale
Patient cohort
Critical ill population
The emergence of COVID19
COVID19 nasal swabs
Questions
Planning is priceless
How quickly the virus spread